Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Οι συνταγές μου Αποθηκεύστε τις συνταγές σας και μοιραστείτε τις εύκολα και με ασφάλεια
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Συνδρομές Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Ενδείξεις και αγωγές Βρείτε θεραπευτικές ενδείξεις και αγωγές για νόσους, συμπτώματα και ιατρικές πράξεις
Γνωρίζατε ότι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα

FENOFIBRATE Hard capsule (2023)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

Fenofibrate 200 mg capsules.

Qualitative and quantitative composition

Each capsule contains 200 mg micronised fenofibrate. Excipient with known effect: Each capsule contains 46.34 mg lactose monohydrate. This capsule also contains sunset yellow FCF (E110). For the full list ...

Pharmaceutical form

Hard capsule. Orange cap/orange body, self locked hard gelatin capsules of size 0 imprinted with FB200 on cap and body containing white to off white granular powder.

Therapeutic indications

Fenofibrate is indicated as an adjunct to diet and other non-pharmacological treatment (e.g. exercise, weight reduction) for the following: Treatment of severe hypertriglyceridaemia with or without low ...

Posology and method of administration

Dietary measures initiated before therapy should be continued. Response to therapy should be monitored by determination of serum lipid values. If an adequate response has not been achieved after several ...

Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Hepatic insufficiency (including biliary cirrhosis and unexplained persistent liver function abnormality). Known ...

Special warnings and precautions for use

Secondary causes of hyperlipidaemia Secondary causes of hyperlipidemia, such as uncontrolled type 2 diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemia, obstructive liver disease, pharmacological ...

Interaction with other medicinal products and other forms of interaction

Oral anti-coagulants Fenofibrate enhances oral anti-coagulant effect and may increase risk of bleeding. In patients receiving oral anti-coagulant therapy, the dose of anti-coagulant should be reduced by ...

Fertility, pregnancy and lactation

Pregnancy There are no adequate data from the use of fenofibrate in pregnant women. Animal studies have not demonstrated any teratogenic effects. Embryotoxic effects have been shown at doses in the range ...

Effects on ability to drive and use machines

Fenofibrate 200 mg Capsules have no or negligible influence on the ability to drive and use machines.

Undesirable effects

The most commonly reported ADRs during Fenofibrate therapy are digestive, gastric or intestinal disorders. The following undesirable effects have been observed during placebo-controlled clinical trials ...

Overdose

Only anecdotal cases of fenofibrate overdosage have been received. In the majority of cases no overdose symptoms were reported. No specific antidote is known. If overdose is suspected, treat symptomatically ...

Pharmacodynamic properties

<b>Pharmacotherapeutic group:</b> Serum Lipid Reducing Agents/Cholesterol and Triglyceride Reducers/Fibrates. <b>ATC code:</b> C10AB05 Fenofibrate 200 mg Capsules are a formulation containing 200 mg of ...

Pharmacokinetic properties

Absorption Maximum plasma concentrations (C<sub>max</sub>) occur within 4 to 5 hours after oral administration. Plasma concentrations are stable during continuous treatment in any given individual. <b> ...

Preclinical safety data

In a three-month oral nonclinical study in the rat species with fenofibric acid, the active metabolite of fenofibrate, toxicity for the skeletal muscles (particularly those rich in type I slow oxidative ...

List of excipients

<>Intragranular:</u> Sodium lauryl sulphate Lactose Pregelatinised starch Crospovidone <u>Extragranular:</u> Crospovidone Pregelatinised starch Talc Colloidal anhydrous silica Magnesium stearate <u>Capsule: ...

Incompatibilities

Not applicable.

Shelf life

2 years.

Special precautions for storage

Store in the original package. Do not store above 25°C.

Nature and contents of container

Blister strip of clear transparent PVC film coated with PVdC on the inner side with a backing of aluminium foil. Pack size of 10, 14, 20, 28, 30, 56, 60 or 90 capsules. Not all pack sizes may be marketed. ...

Special precautions for disposal and other handling

No special requirements.

Marketing authorization holder

SUN PHARMA UK LIMITED, 6-9 The Square, Stockley Park, Uxbridge, UB11 1FW, United Kingdom

Marketing authorization number(s)

PL 14894/0368

Date of first authorization / renewal of the authorization

01/01/2012

Date of revision of the text

18/08/2023

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:

Μπορείτε να υποστηρίξετε τον Γαληνό στην αποστολή του να παρέχει δωρεάν έγκυρη πληροφόρηση για κάθε φάρμακο απενεργοποιώντας το Ad Blocker για αυτόν τον ιστότοπο.